Your Cart

Chinese language diabetes drugs authorised to be used in Pakistan

BEIJING: The insulin glargine injections developed by a Chinese language pharmaceutical firm has been authorised for diabetes sufferers in Pakistan.

The insulin glargine injecta BASAGINE developed acquired approval for registration (Reg. No. 111178) by the Drug Regulatory Authority of Pakistan (DRAP), China Financial Web (CEN) reported on Friday.

In line with the corporate, it’s the first insulin glargine injection (prefilled injection pen) biosimilar drug in Pakistan.

Insulin glargine injection is an important long-acting insulin analogue product within the therapy of diabetes for its efficacy and security.

In Pakistan, 33 million individuals aged 20-79 had been dwelling with diabetes in 2021, rating third on this planet after China and India. The prevalence of diabetes amongst adults aged 20-79 in Pakistan is 30.8 %, the very best on this planet, as per the newest knowledge launched by the Worldwide Diabetes Federation (IDF) World Diabetes Overview tenth Version (2021).

It’s realized that the general marketplace for insulin in Pakistan is over $50 million. Sanofi, Novo Nordisk and Eli Lilly have taken the vast majority of the market share within the nation, and the Chinese language product will deliver extra high quality choices to Pakistani sufferers.

“Since 2010, the pharmaceutical commerce between China and Pakistan has maintained good momentum. As China eases its Covid restriction, we consider that this momentum will proceed to strengthen”, the corporate added.

× WhatsApp